Possible mechanism for the anti-atherosclerotic action of the calcium channel blocker AE0047 in cholesterol-fed rabbits

Clinical and Experimental Pharmacology and Physiology

Volumn 25, Issue 1, 1998, Pages 17-25

  Hayashi, Kazutaka ^a,b   Imada, Teruaki ^a   Yamauchi, Takeshi ^a   Kido, Hideaki ^a   Shinyama, Hiroshi ^a   Matzno, Sumio ^a   Nakamura, Norifumi ^a   Kagitani, Yoshio ^a  

^a Green Cross Company   (South Korea)

^b Research Division   (Japan)

Author keywords

AE0047; Anti atherosclerosis; Calcium channel blocker; Cholesterol esterification; Low density lipoprotein oxidation

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NILVADIPINE; OXIDIZED LOW DENSITY LIPOPROTEIN; WATANIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; DIET; HYPERTENSION; LIPID METABOLISM; LIPID STORAGE; MACROPHAGE; MALE; NONHUMAN; RABBIT;

EID: 0031931746     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1998.tb02137.x     Document Type: Article

References (46)

1. Bonaa KH, Thelle DS. Association between blood pressure and serum lipids in a population. Circulation 1991; 83: 1305-14.
2. Criqui MH, Barrett-Connor E, Holdbrook MJ, Austin M, Turner JD. Clustering of cardiovascular disease risk factors. Prev. Med. 1980; 9: 525-33.
3. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure Study. JAMA 1990; 264: 354-8.
4. Ohtaki Y, UchidaT, Kido H, Watanabe M. Effects of the novel Ca entry blocker (AE0047) on cerebral circulation. Jpn. J. Pharmacol. 1989; 49: 210P.
5. Hayashi K, Gohda M, Matzno S et al. Possible mechanism of action of AE0047, a novel calcium antagonist, on triglyceride metabolism. J. Pharmacol. Exp. Ther. 1997; 282: 882-90.
6. Kobayashi M, Ishida F, Takahashi T et al. Preventive effect of MK-733 (simvastatin), an inhibitor of HMG CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn. J. Pharmacol. 1989; 49: 125-33.
7. Daugherty A, Zweifel BS, Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br. J. Pharmacol. 1989; 98: 612-18.
8. Fennessy PA, Campbell JH, Campbell GR. Prindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis 1994; 106: 29-41.
9. Henry PD. Calcium antagonists as anti-atherosclerotic agents. Arteriosclerosis 1990; 10: 963-5.
10. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total cholesterol. Clin. Chem. 1974; 20: 470-5.
11. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin. Chem. 1982; 28: 2077-80.
12. Matzno S, Gohda M, Eda M et al. A possible mechanism of action of a new potassium channel opener, AL0671, on lipid metabolism in obese Zucker rats. J. Pharmacol. Exp. Ther. 1994; 271: 1666-71.
13. Willis AL, Nagel B, Churchill V et al. Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis 1985; 5: 250-5.
14. Kunitomi M, Yamaguchi Y, Matsushima K, Bando Y. Cholesterol metabolism in serum and aorta of inbred mice fed a high-cholesterol diet. Jpn. J. Pharmacol. 1989; 34: 153-8.
15. Gitelman HJ. An improved automated procedure for the determination of calcium in biological specimens. Anal. Biochem. 1967; 18: 521-31.
16. Basu SK, Goldstein JL, Anderson RGW, Brown MS. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc. Natl Acad. Sci. USA 1976; 73: 3178-82.
17. Goldstein JL, Ho YK, Basu SK, Brown M. Binding site on macrophages that mediates uptake and degradation and acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl Acad. Sci. USA 1979; 76: 333-7.
18. Bilheimer D, Eisenberg S, Levy R. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta 1972; 260: 212-21.
19. Hoff HF, Whitaker TE, O'Neil J. Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition. J. Biol. Chem. 1992; 267: 602-9.
20. Quinn MT, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc. Natl Acad. Sci. USA 1985; 82: 5949-53.
21. Bernini F, Bellosta GD, Fumagalli R. Calcium antagonists and cholestheryl ester metabolism in macrophages. J. Cardiovasc. Pharmacol. 1989; 18 (Suppl. 10): S42-5.
22. Koibuchi Y, Sakai S, Miura S, Ono T, Shibayama F, Ohtsuka M. Suppression of atherogenesis in cholesterol-fed rabbits treated with nilvadipine, a new vasoselective calcium entry blocker. Atherosclerosis 1989; 79: 147-55.
23. Nayler WG, Panagiotopoulos S. The antiatherosclerotic effect of the calcium antagonists and their implications in hypertension. Am. Heart J. 1993; 125: 626-9.
24. Janero DR, Burghardt B. Antiperoxidant effects of dihydropyridine calcium antagonists. Biochem. Pharmacol. 1989; 38: 4344-8.
25. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells: Correlation of protection with preservation of glutathione levels. Circ. Res. 1992; 70: 1099-103.
26. Steinberg D. Antioxidant and atherosclerosis. Circulation 1991; 84: 1420-5.
27. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implication for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 1983; 52: 223-61.
28. Schwartz CJ, Valente AJ, Sprague EA. A modern view of atherogenesis. Am. J. Cardiol. 1993; 71: B9-14.
29. Yamanaga K, Shinyama H, Akira T et al. AE0047-mediated calcium channel blocking in vascular smooth muscles. Gen. Pharmacol. 1997; 29: 337-43.
30. Gotoh N, Shimizu K, Komuro E, Tsuchiyama J, Noguchi H, Niki E. Antioxidant activities of probucol against lipid peroxidations. Biochim. Biophys. Acta 1992; 1128: 147-54.
31. Kondo N, Ashimori A, Ono S et al. Chemical structure and physicochemical properties of (+)-2-[4-(4-benzhydrylpiperazin-1-yl)phenyl] ethyl methyl,1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate dihydrochloride (AE0047). Iyakuhin Kenkyu 1997; 28: 272-86 (in Japanese).
32. Masumoto K, Takeyasu A, Oizumi K, Kobayashi T. Studies of novel 1,4-dihydropyridine Ca antagonist CS-905.I. Measurement of partition coefficient (log P) by high performance liquid chromatography (HPLC). Yakugaku Zasshi 1995; 115: 213-20 (in Japanese).
33. 2 production in cerebral microvessels of stroke-prone spontaneously hypertensive rats. Jpn. Pharmacol. Ther. 1997; 25: 1347-53 (in Japanese).
34. 1) decreases the low-density lipoprotein (LDL)-entry into rabbit arterial wall. Br. J. Pharmacol. 1991; 103: 1626-8.
35. Fong LG, Parthasarathy S, Witztum JL, Steinberg D. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J. Lipid Res. 1987; 28: 1466-77.
36. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-9.
37. Kasiske BL, O'Donnell MP, Schmitz PG et al. The renal injury of diet-induced hypercholesterolemia in rats. Kidney Int. 1990; 37: 880-91.
38. 2, leukotrienes and free radicals in puromycin nephrosis in rats. Kidney Int. 1991; 39: 920-9.
39. Hayashi K, Koyama M, Kido H et al. Preventative and therapeutic effects of AE0047 on renal injury in stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1997; 24: 831-40.
40. Shinyama H, Nagai H, Kawamura T et al. Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 1995; 272: 911-19.
41. Stier CT Jr, Chander P, Gutstein WH, Levine S, Itskovitz HD. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypertensive effects. Am. J. Hypertens. 1991; 4: 680-7.
42. Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ. Res. 1974; 34-35 (Suppl. 1): 143-53.
43. Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke: The Framingham study. JAMA 1970; 214: 301-10.
44. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med. 1989; 320: 904-10.
45. Uchida T, Ohtaki Y, Ogura Y, Watanabe M. Effects of the novel Ca entry blocker (AE0047) on cerebral circulation. Jpn. J. Pharmacol. 1989; 49: 217P.
46. Kido H, Uchida Y, Nakamura F, Sugimoto T. Angiographic studies on the effects of a novel calcium antagonist AE0047 on cerebral arteries in dogs, with special reference to the preventive effects of AE0047 on cerebral vasoconstriction induced by endothelin. Folia Pharmacol. Jpn. 1990; 95: 177-84.